1.
Characteristics | Maintenance/Consolidation chemotherapy (n=29) | Salvage chemotherapy (n=24) | P |
ALP: alkaline phosphatase; LDH: lactate dehydrogenase; PS: performance status. | |||
Age, yr, median (range) | 53 (40-70) | 57 (41-78) | 0.19 |
Sex (n/%) | 0.74 | ||
Male | 24 (82.8%) | 19 (72.9%) | |
Female | 5 (17.2%) | 5 (20.8%) | |
Age group (n/%) | 0.79 | ||
≥65 | 26 (89.7%) | 20 (83.3%) | |
< 65 | 3 (10.3%) | 4 (16.7%) | |
Stage (n/%) | 0.28 | ||
Limit stage | 21 (72.4%) | 14 (58.3%) | |
Extensive stage | 8 (27.6%) | 10 (41.7%) | |
ECOG PS (n/%) | 0.35 | ||
0 | 0 (0.0%) | 1 (4.2%) | |
1 | 25 (86.2%) | 19 (79.2%) | |
2 | 4 (13.8%) | 3 (12.5%) | |
3 | 0 (0.0%) | 1 (4.2%) | |
No. of metastatic sites (n/%) | 0.07 | ||
0 | 21 (72.4%) | 14 (58.3%) | |
1 | 8 (27.6%) | 7 (29.2%) | |
2 | 0 (0.0%) | 3 (12.5%) | |
Elevated ALP level (n/%) | 4 (13.8%) | 3 (12.5%) | 0.89 |
Decreased albumin (n/%) | 2 (7.0%) | 5 (20.8%) | 0.28 |
Elevated LDH level (n/%) | 9 (31.0%) | 9 (37.5%) | 0.62 |